Drugs / BG00011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03573505 | Sep 2018 → Nov 2019 | idiopathic pulmonary fibrosis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT01371305 | Jul 2012 → Mar 2017 | idiopathic pulmonary fibrosis | Biogen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG00011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03573505 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody” NCT01371305 ↗ |
| Route | Subcutaneous | “via subcutaneous (SC) injection” NCT01371305 ↗ |